Abstract
Canine B-cell lymphoma is a clinically heterogenous disease; however, it is generally treated as a single disease entity. The purpose of this clinical trial was to prospectively evaluate naïve canine B-cell lymphoma patients using histopathology, flow cytometry (FC) and a standardized chemotherapy protocol to better define subsets of this disease that may respond differently to treatment. Sixty-four dogs with naïve multicentric B-cell lymphoma were treated with a standardized 19-week CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy protocol. Most of the dogs (84.3%) were diagnosed with diffuse large B-cell lymphoma (DLBCL), followed by nodal marginal zone (7.8%), small B-cell (4.7%), Burkitt-like (1.6%) and follicular lymphoma (1.6%). FC confirmed the diagnosis of B-cell lymphoma in all cases. There were no clear phenotyping differences between the subtypes of B-cell lymphoma detectable by our FC panel. The histologic subtypes in this study exhibited a range of forward scatter values on flow cytometry, but all of the DLBCL cases were higher than a value of 469, while the only cases with a lower forward scatter value were follicular lymphoma and diffuse small B-cell lymphoma. Dogs with DLBCL had a significantly better objective response rate to the CHOP protocol (96.3%) than the non-DLBCL subtypes (70%, P =.024). The median progression-free survival time for patients with DLBCL (233 days) was significantly longer than that of all other histopathologic subgroups combined (163 days, P =.0005).
Original language | English (US) |
---|---|
Pages (from-to) | 342-352 |
Number of pages | 11 |
Journal | Veterinary and Comparative Oncology |
Volume | 18 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1 2020 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2019 John Wiley & Sons Ltd
Keywords
- CHOP
- diffuse large B-cell lymphoma
- flow cytometry
- histopathology
- marginal zone lymphoma
PubMed: MeSH publication types
- Evaluation Study
- Journal Article